S Khosla1, S Amin, R J Singh, E J Atkinson, L J Melton, B L Riggs. 1. Endocrine Research Unit, Division of Rheumatology, Department of Laboratory Medicine, and Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. khosla.sundeep@mayo.edu
Abstract
UNLABELLED: In men, measurement of serum testosterone and estradiol levels with immunoassays correlated with mass spectroscopic measurements, and correlations of sex steroids with volumetric bone mineral density were similar. INTRODUCTION: While immunoassays have been used extensively for measurement of serum testosterone (T) and estradiol (E(2)) levels, there is concern about their specificity, particularly at low E(2) levels as present in men. METHODS: We compared T and E(2) measured by mass spectroscopy to levels measured by immunoassay in men (n = 313, age 22 to 91 years) and related these to volumetric bone mineral density (vBMD) at various skeletal sites. RESULTS: Serum T and non-SHBG bound (or bioavailable) T levels by immunoassay correlated well with the corresponding mass spectroscopy measurements (R = 0.90 and 0.95, respectively, P < 0.001); the correlations for serum E(2) measured using the two techniques were less robust (R = 0.63 for total E(2) and 0.84 for bioavailable E(2), P < 0.001). Overall relationships between serum bioavailable T and E(2) levels with vBMD at various skeletal sites were similar for the immunoassay and mass spectroscopic measures. CONCLUSIONS: Although E(2) levels with immunoassay correlate less well with the mass spectroscopic measurements than do the T measurements in men, our findings indicate that the fundamental relationships observed previously between vBMD and the sex steroids by immunoassay are also present with the mass spectroscopic measurements.
UNLABELLED: In men, measurement of serum testosterone and estradiol levels with immunoassays correlated with mass spectroscopic measurements, and correlations of sex steroids with volumetric bone mineral density were similar. INTRODUCTION: While immunoassays have been used extensively for measurement of serum testosterone (T) and estradiol (E(2)) levels, there is concern about their specificity, particularly at low E(2) levels as present in men. METHODS: We compared T and E(2) measured by mass spectroscopy to levels measured by immunoassay in men (n = 313, age 22 to 91 years) and related these to volumetric bone mineral density (vBMD) at various skeletal sites. RESULTS: Serum T and non-SHBG bound (or bioavailable) T levels by immunoassay correlated well with the corresponding mass spectroscopy measurements (R = 0.90 and 0.95, respectively, P < 0.001); the correlations for serum E(2) measured using the two techniques were less robust (R = 0.63 for total E(2) and 0.84 for bioavailable E(2), P < 0.001). Overall relationships between serum bioavailable T and E(2) levels with vBMD at various skeletal sites were similar for the immunoassay and mass spectroscopic measures. CONCLUSIONS: Although E(2) levels with immunoassay correlate less well with the mass spectroscopic measurements than do the T measurements in men, our findings indicate that the fundamental relationships observed previously between vBMD and the sex steroids by immunoassay are also present with the mass spectroscopic measurements.
Authors: S Amin; Y Zhang; C T Sawin; S R Evans; M T Hannan; D P Kiel; P W Wilson; D T Felson Journal: Ann Intern Med Date: 2000-12-19 Impact factor: 25.391
Authors: Joel S Finkelstein; Hang Lee; Sherri-Ann M Burnett-Bowie; J Carl Pallais; Elaine W Yu; Lawrence F Borges; Brent F Jones; Christopher V Barry; Kendra E Wulczyn; Bijoy J Thomas; Benjamin Z Leder Journal: N Engl J Med Date: 2013-09-12 Impact factor: 91.245
Authors: Catalina Norman; Nanette Rollene; Suanne M Weist; Jean R Wigham; Dana Erickson; John M Miles; Cyril Y Bowers; Johannes D Veldhuis Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: Johannes D Veldhuis; Olga P Bondar; Roy B Dyer; Sergey A Trushin; Eric W Klee; Ravinder J Singh; George G Klee Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: Joel S Finkelstein; Hang Lee; Benjamin Z Leder; Sherri-Ann M Burnett-Bowie; David W Goldstein; Christopher W Hahn; Sarah C Hirsch; Alex Linker; Nicholas Perros; Andrew B Servais; Alexander P Taylor; Matthew L Webb; Jonathan M Youngner; Elaine W Yu Journal: J Clin Invest Date: 2016-02-22 Impact factor: 14.808
Authors: A S Cheung; S Baqar; R Sia; R Hoermann; S Iuliano-Burns; T D T Vu; C Chiang; E J Hamilton; E Gianatti; E Seeman; J D Zajac; M Grossmann Journal: Osteoporos Int Date: 2014-05-07 Impact factor: 4.507
Authors: Alvin C Ng; L Joseph Melton; Elizabeth J Atkinson; Sara J Achenbach; Margaret F Holets; James M Peterson; Sundeep Khosla; Matthew T Drake Journal: Bone Date: 2013-02-18 Impact factor: 4.398
Authors: Kristy M Nicks; Shreyasee Amin; L Joseph Melton; Elizabeth J Atkinson; Louise K McCready; B Lawrence Riggs; Klaus Engelke; Sundeep Khosla Journal: Bone Date: 2013-02-26 Impact factor: 4.398
Authors: Catalina Norman; John Miles; Cyril Y Bowers; Johannes D Veldhuis Journal: Am J Physiol Regul Integr Comp Physiol Date: 2013-03-13 Impact factor: 3.619